Keros Therapeutics, Inc. KROS
Set alert
10.76 USD 0.00 0.00%
At close · Nov 2
10.76 0.00 0.00%
After hours · Nov 2, 4:00 PM ET
Day range unavailable
9.69 52-week range 22.55
- YTD
- -47.15%
- 1 year
- -29.30%
- Open
- —
- Prev close
- 10.76
- Mkt cap
- 213.34M
- Vol
- 0
- Avg vol
- 188.53K
- EPS
- -3.15
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -3.00
- Beta
- 1.24
- Short ratio
- 5.28
- Inst. own
- 100.86%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 7, 2024
- 50-d avg
- 55.00
- 200-d avg
- 53.85
- 1y target
- 43.55
Analyst view
Consensus: buy
Buy
Price target (mean) 43.55 +304.7% upside
Now 10.76
- Target (low)
- 23.00
- Target (mean)
- 43.55
- Target (high)
- 76.00
Ratings (0m) 14 11 buy · 3 hold · 0 sell
- Strong buy3
- Buy8
- Hold3
- Sell0
- Strong sell0
Recommendation trend
- This month 14
- 1 month ago 15
- 2 months ago 14
- 3 months ago 11
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.51 | -1.57 – 3.49 | -1.34 | +61.9% | 34.21M | +23821.9% | 12 |
| Next quarter | -1.37 | -1.55 – -1.23 | -1.21 | -13.5% | 22.23M | +26687.1% | 6 |
| Current year | -4.22 | -5.50 – 0.31 | -5.20 | +18.9% | 29.83M | +19656.7% | 11 |
| Next year | -3.86 | -6.55 – 2.06 | -4.22 | +8.6% | 33.29M | +11.6% | 12 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 23, 2024 | Truist Securities | Maintained | Buy | Buy |
| Dec 16, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| Dec 16, 2024 | Guggenheim | Downgrade | Buy | Neutral |
| Dec 13, 2024 | Scotiabank | Maintained | Sector Outperform | Sector Outperform |
| Dec 13, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Dec 12, 2024 | William Blair | Downgrade | Outperform | Market Perform |
| Dec 12, 2024 | TD Cowen | Downgrade | Buy | Hold |
| Dec 12, 2024 | BTIG | Downgrade | Buy | Neutral |
| Dec 11, 2024 | Wells Fargo | Maintained | Overweight | Overweight |
| Dec 5, 2024 | Guggenheim | Maintained | Buy | Buy |
| Dec 4, 2024 | Guggenheim | Reiterated | Buy | Buy |
| Nov 22, 2024 | Cantor Fitzgerald | Reiterated | — | Overweight |
| Nov 7, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Oct 24, 2024 | Cantor Fitzgerald | Reiterated | — | Overweight |
| Oct 16, 2024 | Scotiabank | Initiated | — | Sector Outperform |
| Sep 23, 2024 | Guggenheim | Initiated | — | Buy |
| Sep 12, 2024 | B of A Securities | Maintained | Buy | Buy |
| Jun 25, 2024 | Oppenheimer | Initiated | — | Outperform |
| Jun 18, 2024 | Truist Securities | Maintained | Buy | Buy |
| Jun 18, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 9, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 27, 2024 | Piper Sandler | Maintained | Overweight | Overweight |
| Mar 13, 2024 | Truist Securities | Reiterated | Buy | Buy |
| Mar 1, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Dec 8, 2023 | Wells Fargo | Initiated | — | Overweight |
| Nov 13, 2023 | Wedbush | Reiterated | Outperform | Outperform |
| Aug 31, 2023 | Wedbush | Reiterated | Outperform | Outperform |
| Aug 9, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 8, 2023 | Wedbush | Reiterated | Outperform | Outperform |
| Aug 7, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |